GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (TSXV:NGEN) » Definitions » Capex-to-Operating-Income

NervGen Pharma (TSXV:NGEN) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is NervGen Pharma Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

NervGen Pharma's Capital Expenditure for the three months ended in Dec. 2023 was C$0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was C$-4.88 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


NervGen Pharma Capex-to-Operating-Income Historical Data

The historical data trend for NervGen Pharma's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma Capex-to-Operating-Income Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

NervGen Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NervGen Pharma's Capex-to-Operating-Income

For the Biotechnology subindustry, NervGen Pharma's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NervGen Pharma's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NervGen Pharma's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where NervGen Pharma's Capex-to-Operating-Income falls into.



NervGen Pharma Capex-to-Operating-Income Calculation

NervGen Pharma's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.141) / -17.777
=N/A

NervGen Pharma's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -4.875
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NervGen Pharma  (TSXV:NGEN) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


NervGen Pharma Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


NervGen Pharma (TSXV:NGEN) Business Description

Traded in Other Exchanges
Address
2955 Virtual Way, Suite 480, Vancouver, BC, CAN, V5M 4X6
NervGen Pharma Corp is a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases. The company is developing drugs for the treatment of spinal cord injury, multiple sclerosis, and Alzheimer's disease. It operates in a single segment, which is the research and development of pharmaceutical drugs.

NervGen Pharma (TSXV:NGEN) Headlines

No Headlines